Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight

Evotec – Tension is rising

Yesterday, Evotec made a significant market entry with a big surprise. The Hamburg-based company announced progress in its strategic partnership with Bristol Myers Squibb, which focuses on building a pipeline of molecular glues. Scientific breakthroughs support the development of molecular glue degraders in non-oncology therapeutic areas, triggering a previously agreed milestone payment of USD 50 million to Evotec. Additional program-related achievements will thus further increase the value of the collaboration. The partnership, which has been in place since 2018, is beginning to pay off in tangible ways. The goal of the collaboration remains to establish a leading position for high-value therapeutic targets outside of oncology.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are pleased to extend our successful partnership with Bristol Myers Squibb into areas of major unmet medical need outside of oncology. Molecular glue degraders offer a promising therapeutic option due to their unique mode of action, similarity to drugs and the possibility of oral administration." Thanks to positive news, the jump over the EUR 6 mark seems to have succeeded. It leads us to revisit the short positions, which might soon be closed. Speculative investors can act now, while conservative investors wait for the Q3 figures and outlook on November 6. Very exciting!

Vidac Pharma – Investors applaud the latest progress

This is slowly turning into a long-term story. We have reported on Vidac Pharma plc several times in recent weeks. There has been tremendous interest in the stock recently, and even with a premium of 300% at the peak, there are now further potential buyers. Last week, the price briefly reached EUR 1.30, which seems a bit excessive in such a short time. At the peak, around 4 million shares changed hands. Since the last report on the granting of a patent for extensive protection of the mode of action of its cancer drug candidates, there have been no new insights. Presumably, expectations are high for further progress in the Israeli research program at the upcoming medical conferences in Q4, particularly regarding the drug candidates VDA-1102 and VDA-1275.

It is also conceivable that the current analysis from Sphene Capital has fallen into the right hands and that a decent position has been built up in the market. Vidac Pharma's last capital increase was some time ago. Perhaps this level will now be used to top up the coffers a little. In June, we pointed out the share's attractiveness at EUR 0.19. This is especially true now, as the market is clearly aiming for a rapid revaluation.

Bayer and BioNTech – Progress is visible

A development comparable to Vidac's would mean a multi-billion-dollar revaluation for Bayer and BioNTech. But in the case of Bayer, patience is still required, as there is a constant stream of bad news from the US glyphosate litigation front. Although the share price briefly crossed the EUR 29 mark in September, it has now fallen again by 10% to EUR 25.70. CEO Bill Anderson expects savings of up to EUR 2 billion from next year onwards due to streamlining management levels, with the restructuring plan to be completed by mid-2025. Since the restructuring began, 3,200 jobs have already been cut worldwide, and Anderson expects the same number to follow by the end of 2025.

The balance sheet for the last 6 years resembles a horror movie. Before the 2018 acquisition of Monsanto, the share price was still around EUR 120 per share. If you include Monsanto's market capitalization in this calculation, the fair value per Bayer share would currently be just over EUR 160, around 500% above the current price. So much for the analysis! Meanwhile, hopes at Bayer are pinned on the new cancer drug Nubeqa. An application for approval extension has now also been submitted in Europe for this drug. The financial community is at the ready and hoping for quick improvements. The Q3 report is expected on November 5. Exciting!

BioNTech has seen a gratifying 30% increase in the last six weeks. The good mood is based on the buzzword "artificial intelligence." BioNTech held an event on this topic in London at the beginning of October. Last year, the Mainz-based company acquired the service provider InstaDeep for USD 500 million. The aim is to build an AI-powered, personalized immunotherapy platform. This should help in the discovery and development of therapies and mRNA cancer vaccines. Investors have high expectations for the new developments, with more news coming on November 4 with the Q3 report. Chart-wise, the value should not drop below EUR 97. This is also where we set the stop for the most recent follow-up purchases in the EUR 78 to 86 range. BioNTech is enticing, with cash of EUR 17 billion and a market capitalization of only EUR 23.5 billion.**

Speculation is reviving! Low interest rates and bombed-out prices are inviting investors to buy beaten-down biotech stocks, as seen with Vidac Pharma and Evotec. If declining inflation causes central banks to cut interest rates further, the doldrums in the entire sector should soon be a thing of the past. A healthy diversification strategy can help reduce portfolio risk.